Pliant Therapeutics Inc (PLRX) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC...

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today...

Form 8-K - Current report

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report